Korro Bio, Inc. (KRRO) - Q2 2025 10-Q Summary
Business Context and Reporting Period
Korro Bio, Inc. is a clinical-stage biopharmaceutical company developing genetic medicines based on RNA editing technology. This report covers the quarterly period ended June 30, 2025. The Company is currently advancing its lead product candidate, KRRO-110, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) in the Phase 1/2a REWRITE clinical trial. In May 2025, the Company initiated a workforce reduction of 19% (21 positions) to streamline operations.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Collaboration Revenue | $1.46 million | $0 | $4.01 million | $0 |
| Total Operating Expenses | $28.66 million | $24.13 million | $56.23 million | $45.58 million |
| Net Loss | $(25.77) million | $(21.83) million | $(49.16) million | $(41.38) million |
| Net Loss Per Share (Basic/Diluted) | $(2.74) | $(2.43) | $(5.24) | $(4.87) |
| Cash, Cash Equivalents & Marketable Securities | $119.6 million (as of June 30, 2025) | |||
| Accumulated Deficit | $315.7 million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Revenue Recognition: The Company recognized $4.01 million in collaboration revenue for the six months ended June 30, 2025, primarily from its September 2024 agreement with Novo Nordisk. No collaboration revenue was recognized in the comparable 2024 period.
- Expense Increases: Operating expenses increased by $10.65 million year-over-year for the six-month period. Research and Development (R&D) expenses rose by $10.06 million, driven by increased clinical trial costs for the REWRITE trial and personnel expenses prior to the May 2025 workforce reduction.
- Restructuring Costs: The Company recorded one-time severance charges of approximately $1.2 million in Q2 2025 related to the 19% workforce reduction.
- Liquidity: Cash and marketable securities decreased from $164.0 million at year-end 2024 to $119.6 million at June 30, 2025, reflecting a net cash burn of $22.0 million for the six-month period.
Guidance, Outlook, and Risks
- Clinical Progress: The Company has dosed over 80% of planned healthy volunteers in the REWRITE trial. Interim data is expected in the second half of 2025, with trial completion anticipated in 2026. The Company plans to announce a development candidate for its rare metabolic disorder program by the end of 2025.
- Cash Runway: Management expects existing cash, cash equivalents, and marketable securities ($119.6 million) to fund operations into 2027, covering the completion of the REWRITE trial and other milestones.
- Collaboration Revenue: Revenue from the Novo Nordisk agreement is expected to be recognized through the first quarter of 2027.
- Risks: Key risks include the uncertainty of clinical trial outcomes for RNA editing technologies, the need for substantial additional funding if capital markets tighten, and potential delays in patient enrollment or regulatory approvals. The Company has not generated any revenue from product sales and expects to incur losses for the foreseeable future.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $119.6 million cash balance against the projected burn rate into 2027, considering the recent workforce reduction.
- Novo Nordisk Revenue: Confirm the timing and magnitude of future revenue recognition from the $39.9 million total transaction price with Novo Nordisk.
- REWRITE Trial Data: Monitor the release of interim data from the Phase 1/2a trial in late 2025 for safety and efficacy signals.
- Restructuring Impact: Assess whether the 19% workforce reduction successfully lowers the operating expense base as intended.
- Capital Needs: Evaluate the Company's ability to raise additional capital if clinical milestones are delayed or if the cash runway shortens.